MSD (Schering-Plough)

Project with the company MSD (Schering-Plough)

Developing in Ukraine the strategic direction of its activity on creation of partnership projects with the world's leading pharmaceutical companies as part of the state program of import substitution, in order to improve access to innovative medicines, in 2011the company “Lumiere Pharma” concluded the agreement on a joint project for the production of products with a world leader – pharmaceutical company MSD (Schering-Plough).
In November 2012 the preparation UNITRON (PEG-interferon alpha-2b) was registered (production from «in bulk» of the company MSD (Schering-Plough) in two dosage forms:
     - Lyophilized powder for solution for injection in a vial of 50μg/0.5 mL, 80 μg/0.5mL, 100μg/0.5 mL, 120μg/0.5 mL, 150 μg/0.5 ml 5 together with the solvent;
     - Lyophilized powder for solution for injection in adual-chamber injection pen (redipen) of 50μg/0.5 mL, 80 μg/0.5mL, 100μg/0.5mL, 120μg/0.5 mL, 150 μg/ 0.5 ml with the solvent.
The preparatiom UNITRON (PEG-interferon alfa-2b) is used to treat chronic hepatitis B and C in adults and children.
Implementation of joint projects in a socially significant segment of the healthcare of Ukraine will allow increasing patient access to innovative high-tech immunobiological products, receiving treatment in accordance with the international standards of treatment of viral hepatitis.